In a defining moment for public health, former controller general P.H. Kurian reshaped healthcare access through a historic 2012 verdict.

In his final judgment, Kurian issued a groundbreaking compulsory license on Bayer’s kidney cancer drug, Nexavar, effectively dismantling the pharmaceutical giant's monopoly.

The decisive ruling allowed local generic production, slashing the medication's exorbitant cost by approximately 97 percent and securing affordable, life-saving treatment for countless vulnerable patients.